The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis

Abstract

Background

Patients with homozygous familial hypercholesterolemia are at high risk of cardiovascular disease due to high low-density lipoprotein (LDL)-cholesterol levels. Cardiovascular disease outcome studies are impossible to conduct, due to the rarity of homozygous familial hypercholesterolemia. We modelled the potential efficacy of lomitapide, a microsomal transfer protein inhibitor, on major adverse cardiovascular events (MACEs) and survival.

Design

We calculated the effect on cardiovascular outcomes of a 38% plasma LDL-cholesterol reduction induced by lomitapide.

Methods

Age-dependent hazards and treatment-dependent hazard ratios for mortality and time to first MACE were calculated from an observational study of 149 South African homozygous familial hypercholesterolemia patients. Cardiovascular-related mortality hazards were derived by adjusting for general population non-cardiovascular-related mortality. For every mmol/L LDL-cholesterol reduction, a relative risk reductions of 23% (mortality) and 15% (major adverse cardiovascular events) were observed.

Results

For the most robust model, baseline median survival with current treatments (LDL-cholesterol 8.7 mmol/L) was 48 years. In the survival benefit analysis, starting lomitapide at age 18 years and reducing LDL-cholesterol by 3.3 mmol/L from baseline would increase life expectancy by 11.2 years and delay the time to first MACE by 5.7 years. Analysis suggested lifetime lomitapide treatment could increase median life expectancy by 11.7 years and time to first MACE by 6.7 years.

Conclusion

Our modelling analyses show that additional LDL-cholesterol lowering by lomitapide may increase life expectancy in patients with homozygous familial hypercholesterolemia. Further clinical studies are warranted to determine the cardiovascular morbidity and mortality benefits of lomitapide.

Keywords

Familial hypercholesterolemia LDL-cholesterol survival analysis proportional hazards model

Get full access to this article

View all access options for this article.

References

Raal

Santos

. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223: 262–268.

Sjouke

Kusters

Kindt

et al.

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36: 560–565.

Benn

Watts

Tybjaerg-Hansen

et al.

Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97: 3956–3964.

Cuchel

Meagher

du Toit Theron

et al.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381: 40–46.

LaRosa

Vupputuri

. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.

Delahoy

Magliano

Webb

et al.

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009; 31: 236–244.

Cuchel M, Blom DJ, Averna M, et al. Sustained LDL-C lowering and stable hepatc fat levels in patients with homozygous familial hypercholesterolemia treated with the microsomal transfer protein inhibitor lomitapide: results of an ongoing long-term extension study. Dallas, Texas: American Heart Association Scientific Sessions, 2013, Abstract 16516.

Raal

Pilcher

Panz

et al.

Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124: 2202–2207.

Cholesterol Treatment Trialists Collaboration

Baigent

Blackwell

et al.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

10.

Ference

Yoo

Alesh

et al.

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631–2639.

11.

Wyndham

. Mortality from cardiovascular diseases in the various population groups in the Republic of South Africa. South African medical journal [Suid-Afrikaanse tydskrif vir geneeskunde] 1979; 56: 1023–1030.

12.

Wyndham

Irwig

. A comparison of the mortality rates of various population groups in the Republic of South Africa. South African medical journal [Suid-Afrikaanse tydskrif vir geneeskunde] 1979; 55: 796–802.

13.

Raal

Santos

Blom

et al.

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998–1006.

14.

Raal FJ, Honarpour N, Blom DJ, et al. Trial evaluating evolocumab, a PCSK9 antibody in patients with homozygous FH (TESLA): results of the randomised, double-blind placebo-controlled trial. Madrid, Spain: European Atherosclerosis Society, 2014, Abstract 1177.

15.

Horton

Cohen

Hobbs

. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(Suppl.): S172–S177.

16.

Murphy

Cannon

Blazing

et al.

Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 2016; 67: 353–361.

17.

JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100(Suppl. 2): ii1–ii67.

18.

Cuchel

Bruckert

Ginsberg

et al.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–2157.

19.

Watts

Gidding

Wierzbicki

et al.

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol 2015; 22: 849–854.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.60 MB